Timely access to trial data in the context of a pandemic: the time is now. Issue 10 (29th October 2020)

• Record Type: Journal Article
• Authors: Li, Rebecca; Wood, Julie; Baskaran, Amrutha; Neumann, Stanley; Graham, Elizabeth; Levenstein, Marcia; Sim, Ida
• Is Part Of: BMJ open. Volume 10:Issue 10(2020)
• Publication Date: 2020-10-29
• Subjects: information management -- information technology -- public health -- statistics & research methods -- public health; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2020-039326
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Objective: Clinical trial data sharing has the potential to accelerate scientific progress, answer new lines of scientific inquiry, support reproducibility and prevent redundancy. Vivli, a non-profit organisation, operates a global platform for sharing of individual participant-level trial data and associated documents. Sharing of these data collected from each trial participant enables combining of these data to drive new scientific insights or assess reproducibility—not possible with the aggregate or summary data tables historically made available. We report on our initial experience including key metrics, lessons learned and how we see our role in the data sharing ecosystem. We also describe how Vivli is addressing the needs of the COVID-19 challenge through a new dedicated portal that provides a direct search function for COVID-19 studies, availability for fast-tracked request review and data sharing. Data summary: The Vivli platform was established in 2018 and has partnered with 28 diverse members from industry, academic institutions, government platforms and non-profit foundations. Currently, 5400 trials representing 3.6 million participants are shared on the platform. From July 2018 to September 2020, Vivli received 201 requests. To date, 106 of 201 requests received approval, 5 have been declined, 27 withdrew and 27 are in the revision stage. Conclusions: The pandemic has only magnified the necessity for data sharing. If most data are shared and in a manner that allows interoperability, then we have hope of moving towards a cohesive scientific understanding more quickly not only for COVID-19 but also for all diseases. Conversely, if only isolated pockets of data are shared then society loses the opportunity to close vital gaps in our understanding of this rapidly evolving epidemic. This current challenge serves to highlight the value of data sharing platforms—critical enablers that help researchers build on prior knowledge.